ProfileGDS5678 / 1445668_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 65% 66% 65% 65% 66% 64% 65% 65% 66% 63% 68% 73% 65% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3949470
GSM967853U87-EV human glioblastoma xenograft - Control 23.9240465
GSM967854U87-EV human glioblastoma xenograft - Control 33.966666
GSM967855U87-EV human glioblastoma xenograft - Control 43.9115265
GSM967856U87-EV human glioblastoma xenograft - Control 53.9028365
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0512766
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9246964
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9418965
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8947765
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.9744766
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7561163
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.152868
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.6929573
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.882565